Targeted immunotherapy

Show results for

Unknown (6774)
Transcriptomics (1086)
Genomics (554)
Proteomics (110)
Other (32)
Clinical (21)
Metabolomics (13)
Methylation profiling (6)
Models (3)
Genomic (3)
Multiomics (1)

Organisms

Homo sapiens (488)
Mus musculus (438)
Drosophila melanogaster (38)
Arabidopsis thaliana (28)
Rattus norvegicus (18)
Saccharomyces cerevisiae (16)
Danio rerio (15)
Sus scrofa (8)
Caenorhabditis elegans (7)
Bos taurus (6)
Zea mays (4)
Campylobacter jejuni (4)
Solanum lycopersicum (4)
Gallus gallus (4)
Macaca mulatta (3)
Oryza sativa Japonica Group (3)
Canis lupus familiaris (3)
Boehmeria nivea (2)
Campylobacter jejuni subsp. jejuni NCTC 11168 = ATCC 700819 (2)
Hevea brasiliensis (2)
environmental samples (2)
Thermus thermophilus HB8 (2)
Brugia pahangi (2)
Pan troglodytes (2)
Drosophila simulans (2)
Xenopus laevis (2)
Schizosaccharomyces pombe (2)
Vitis vinifera (2)
Mycobacterium tuberculosis (2)
Oncorhynchus mykiss (2)

Organisms

Homo sapiens (214)
Mus musculus (177)
Shewanella oneidensis MR-1 (1)
Human immunodeficiency virus 1 (1)
Muroidea (1)
Mammalia (1)
Bacteria (1)
Canis lupus familiaris (1)
Danio rerio (1)

Repository

biostudies-arrayexpress (825)
ENA (487)
geo (345)
pride (74)
EGA (22)
iProX (22)
MetaboLights (13)
MassIVE (8)
BioModels (3)
dbGaP (3)
jPOST (2)
EVA (1)
GPMDB (1)
NODE (1)
PanoramaPublic (1)

Tissue

Cell culture (28)
Brain (10)
Blood (8)
Lung (8)
Melanocyte (7)
B cell (6)
Epithelial cell (6)
Permanent cell line cell (5)
Blood cell (4)
Fibroblast (4)
Skin (4)
Cell suspension culture (3)
T cell (3)
Bone marrow (2)
Colon (2)
JURKAT cell (2)
Liver (2)
Macrophage (2)
Peripheral blood mononuclear cell (2)
Pancrease (1)
Blood plasma (1)
Breast cancer cell (1)
Breast cancer stem cell (1)
Cell (1)
Cerebellum (1)
Dendritic cell (1)
Epithelium of pancreatic duct (1)
Heart (1)
Kidney (1)
Lymph node (1)

Disease

Colorectal Neoplasms (11)
Lung cancer (6)
Glioblastoma (4)
Neoplasms (4)
Acute leukemia (4)
Brain cancer (3)
Breast cancer (3)
Malignant neoplasm of ovary (3)
Skin melanoma (3)
Brain glioblastoma multiforme (2)
Colon cancer (2)
Lung small cell carcinoma (2)
Melanoma (2)
Pancreatic ductal adenocarcinoma (2)
XCGD (1)
Huntington's disease mouse model (1)
GIP-dependent Cushing's syndrome (1)
Osteosarcoma subtype fibroblastic (1)
Ewing family tumor (1)
Neuroblastoma (1)
MICROSATELLITE STABLE (MSS) COLORECTAL CANCER WITH LIVER-DOMINANT METASTASIS (1)
Carcinoma, Hepatocellular (1)
Carcinoma (1)
Colonic Neoplasms (1)
Colorectal cancer (1)
Gastrointestinal Neoplasms (1)
Not Available (1)
Pancreatic cancer (1)
Acute myeloid leukemia (1)
Burkitt lymphoma (1)

Technology Type

Mass Spectrometry (74)
Shotgun proteomics (32)
Affinity purification coupled with mass spectrometry proteomics (15)
Data-dependent acquisition (15)
Bottom-up proteomics (12)
Mass spectrometry assay (8)
Immunopeptidomics (8)
Mass spectrometry (5)
Data-independent acquisition (4)
SRM/MRM (4)
Gel-based experiment (2)
SWATH MS (2)
Illumina HiSeq 2500, ILLUMINA (1)
Illumina (1)
NMR spectroscopy assay (1)
Glycoproteomics (1)
Top-down proteomics (1)

Instrument Platform

Illumina NovaSeq 6000 (6)
Illumina HiSeq 4000 (6)
Liquid Chromatography MS - positive - reverse phase (4)
Illumina HiSeq 2500 (3)
Liquid Chromatography MS - negative - reverse phase (3)
Illumina HiSeq 2000 (2)
Orbitrap Fusion Lumos (2)
Liquid Chromatography MS - alternating - hilic (2)
Liquid Chromatography MS - positive - reverse-phase (2)
Liquid Chromatography MS - negative - reverse-phase (2)
Liquid Chromatography MS - positive - hilic (2)
Illumina NovaSeq X (1)
Ion Torrent Proton (1)
Illumina MiSeq (1)
NextSeq 550 (1)
Ion S5XL (1)
Instrument (1)
LTQ Orbitrap Elite (1)
Orbitrap Ascend (1)
Orbitrap Exploris 480 (1)
Q Exactive (1)
Synapt G2 HDMS (1)
Thermo QExactive HF (1)
Liquid Chromatography MS - Alternating (LC-MS (Alternating)) (1)
Nuclear Magnetic Resonance (NMR) - (1)
Liquid Chromatography MS - negative (1)
Liquid Chromatography MS - alternating - reverse-phase (1)
Liquid Chromatography MS - alternating - reverse phase (1)
Liquid Chromatography MS - negative - HILIC (1)
Liquid Chromatography MS - positive - HILIC (1)

Publication Date

2015 (139)
2010 (131)
2013 (123)
2012 (109)
2014 (107)
2025 (97)
2024 (92)
2026 (88)
2011 (78)
2022 (61)
2016 (41)
2021 (39)
2023 (37)
2008 (32)
2020 (25)
2009 (24)
2007 (23)
2019 (18)
2018 (14)
2004 (5)
2005 (4)
2017 (4)
2006 (2)
2003 (1)

CHEBI ID

CHEBI:16027 (4)
CHEBI:16811 (3)
CHEBI:16708 (3)
CHEBI:25017 (3)
CHEBI:29016 (3)
CHEBI:16761 (3)
CHEBI:27897 (3)
CHEBI:17368 (3)
CHEBI:16709 (2)
CHEBI:26271 (2)
CHEBI:17126 (2)
CHEBI:22660 (2)
CHEBI:18186 (2)
CHEBI:16610 (2)
CHEBI:28044 (2)
CHEBI:16393 (2)
CHEBI:17597 (2)
CHEBI:16704 (2)
CHEBI:17750 (2)
CHEBI:15746 (2)
CHEBI:18183 (2)
CHEBI:25094 (2)
CHEBI:6650 (2)
CHEBI:18237 (2)
CHEBI:15971 (2)
CHEBI:16856 (2)
CHEBI:16436 (2)
CHEBI:15741 (2)
CHEBI:32816 (2)
CHEBI:44897 (2)

Metabolite Name

Gluconic acid (3)
Citric acid (3)
Phenylalanine (3)
Hypoxanthine (3)
N-Formylglycine (2)
Galactaric acid (2)
Pyrrole-2-carboxylic acid (2)
UDP-N-acetylglucosamine (2)
Histidine (2)
Leucine (2)
Threonic acid (2)
N6-Acetyllysine (2)
Oxalic acid (2)
Fructose 6-phosphate (2)
N-Acetylaspartic acid (2)
Dimethylglycine (2)
Acetylglycine (2)
Glycine (2)
Uracil (2)
Betaine (2)
Propionylcarnitine (2)
Pyroglutamic acid (2)
N-Acetylglutamic acid (2)
Carnosine (2)
6-Phosphogluconic acid (2)
2-Hydroxybutyric acid (2)
5-Methylcytosine (2)
Phosphoenolpyruvate (2)
Carnitine (2)
Maleic acid (2)

First Public Date

2025 (110)
2026 (89)
2024 (87)
2022 (57)
2023 (45)
2021 (36)
2020 (20)
2019 (13)
2018 (10)
2016 (7)
2014 (7)
2017 (4)
2015 (2)

Modelling Approach

Ordinary differential equation model (3)

Study status

Recruiting (10)
Active, not recruiting (3)
Not yet recruiting (2)
Completed (2)
Ongoing (1)
Suspended (1)
Enrolling by invitation (1)
Withdrawn (1)

Lab affiliation

Department of Oncology-Pathology, Karolinska Institute and Scilifelab, Solna, Sweden (2)
Div. Clinical Protein Science and Imaging, Dept. of Clinical Sciences and Dept. of Biomedical Engineering, Lund University, Sweden (2)
Head of System Biology Lab. at Lopukhin Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency (2)
Moffitt Cancer Center Tampa, FL (2)
Amsterdam UMC, Vrije Universiteit Amsterdam, Medical Oncology, Cancer Center Amsterdam, OncoProteomics Laboratory, Amsterdam, Netherlands (1)
Assistant Professor Department of Cellular and Molecular Medicine Florida International University | Herbert Wertheim College of Medicine (1)
Associate Professor (1)
Attending Physician Medical Director, Brain Tumor Institute Principal Investigator, Center for Cancer and Immunology Research, Children Research Institute Associate Professor of Pediatrics - The George Washington University School of Medicine and Health Sciences Executive co-Chair, Childrens Brain Tumor Network www.CBTN.org (1)
Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Padualaan 8, 3584 CH Utrecht, the Netherlands (1)
BriaCell Therapeutics Corporation, Berkeley, CA, USA (1)
Brown University, MCB Department (1)
Calico Life Sciences (1)
Cancer Signaling and Microenvironment Program,Fox Chase Cancer Center, Philadelphia, PA, USA (1)
Center for Molecular Imaging, Departments of Radiology and Surgery, The University of Michigan, BSRB A502, Ann Arbor, MI 48109, United States. (1)
Cheeloo College of Medicine, Shandong University, Jinan 250002, PR.China. Department of Hepatobiliary Surgery, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China. Anhui Province Key Laboratory of Hepatopancreatobiliary Surgery, Hefei 230001, China. Anhui Provincial Clinical Research Center for Hepatobiliary Diseases, Hefei 230001, China. (1)
Cheeloo College of Medicine, Shandong University, Jinan 250002, PR.China. Department of Hepatobiliary Surgery, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China. Anhui Province Key Laboratory of Hepatopancreatobiliary Surgery, Hefei 230001, China. Anhui Provincial Clinical Research Center for Hepatobiliary Diseases, Hefei 230001, China. (1)
Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tübingen, Tübingen, Germany (1)
Clinical Protein Science & Imaging, Biomedical Centre, Department of Biomedical Engineering, Lund University (1)
Core Unit Proteomics, Berlin Institute of Health at Charité-Universitätsmedizin Berlin and Max-Delbrück-Center for Molecular Medicine, 13125 Berlin, Germany (1)
Department of Biochemistry and Molecular Biology and Infection and Immunity Program, Biomedicine Discovery Institute, Monash University, Clayton 3800, VIC, Australia (1)
Department of Biological Engineering, MIT (1)
Department of Biological Engineering, Massachusetts Institute of Technology (1)
Department of Biology, Technion - Israel Institute of Technology, Haifa, Israel (1)
Department of Clinical Sciences Lund, Section of Oncology, Lund University, Lund 221 85, Sweden (1)
Department of Developmental Biology and Cancer Research, Institute for Medical Research Israel-Canada, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel. (1)
Department of Genetics, Washington University School of Medicine, St. Louis, MO, USA; The Edison Family Center for Genome Sciences and Systems Biology, Washington University School of Medicine, St. Louis, MO, USA; McDonnell Genome Institute, Washington University School of Medicine, St. Louis, MO, USA (1)
Department of Haematology, University of Cambridge (1)
Department of Hematology and Oncology, University of Tübingen, Tübingen, Germany (1)
Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel (1)
Department of Immunobiology University of Lausanne Chemin des Boveresses 155 CH-1066 Epalinges, Switzerland (1)

Keyword

Immunotherapy (8)
Cetuximab (4)
Atezolizumab (3)
Nivolumab (3)
Bevacizumab (3)
Neoantigen Vaccines (2)
Cancer Vaccines (2)
Pancreatic Ductal Adenocarcinoma (PDAC) (2)
Poly ICLC (2)
Interleukin-2 (2)
IL-2 (2)
Anti-PD-1 (2)
PD-1 (2)
Ipilimumab (2)
Irinotecan (2)
Avelumab (2)
Leucovorin (2)
Fluorouracil (2)
Oxaliplatin (2)
Atezolizumab (1)
Enlotinib (1)
Penpulimab (1)
Autologous cytokine induced killer cells (1)
KRAS Peptide Vaccine (1)
Resected MMR-p Colorectal Cancer (1)
Resected MMR-p Pancreatic Cancer (1)
OXALIPLATINE HOSPIRA (1)
CAPÉCITABINE MYLAN (1)
HR+ breast cancer (1)
Adoptive cell therapy (1)

IsPrivate

False (3)

Submitter Keywords

Immuno-oncology (3)

Classification

viruses (1)

Study type

Transcription profiling by array (520)
RNA-seq of coding RNA (108)
Unknown experiment type (39)
ChIP-chip by tiling array (31)
Comparative genomic hybridization by array (25)
RNA-seq of non coding RNA (24)
Interventional (17)
Other (15)
ChIP-seq (14)
Methylation profiling by array (10)
Transcription profiling by SAGE (6)
Transcription profiling by tiling array (6)
RNA-seq of coding RNA from single cells (6)
Animal - High-throughput sequencing (4)
Genotyping by array (3)
Transcription profiling by RT-PCR (3)
Proteomic profiling by array (3)
Observational (3)
MicroRNA profiling by array (2)
Methylation profiling by high throughput sequencing (2)
Proteomic profiling by mass spectrometer (1)
RNAi profiling by array (1)
DNA-seq (1)
Observational patient registry (1)

Release Date

2023 (1048)
2022 (1042)
2025 (990)
2024 (860)
2021 (837)
2020 (548)
2019 (353)
2018 (292)
2015 (232)
2017 (198)
2016 (195)
2014 (179)
2013 (168)
2010 (151)
2026 (144)
2012 (140)
2011 (98)
2008 (39)
2009 (38)
2007 (27)
2006 (8)
2004 (5)
2005 (4)
2003 (2)
2000 (1)

Location

China (6)
United States (5)
South Korea (2)
Italy (2)
France (2)
Rwanda (1)
Norway (1)
Taiwan (1)
Poland (1)
Israel (1)
Australia (1)
United Kingdom (1)
Spain (1)
Belgium (1)
Canada (1)

Previous page
1 / 861
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 861
Next page

Sort by:

Relevance

Page size

Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial

Fecal microbiota transplantation (FMT) represents a potential strategy to overcome resistance to immune checkpoint inhibitors in patients with refractory melanoma; however, the role of FMT in first-line treatment settings has not been evaluated. We conducted a multicenter phase I trial combining ...

2025-02-27 | MTBLS711 | MetaboLights

Metabolic-engineered probiotic-OMVs as nanovaccine mediating sequential immunomodulation for chronic bone infection immunotherapy

Chronic, drug-resistant bone infection caused by methicillin-resistant Staphylococcus aureus (MRSA) features an immunosuppressive niche enabling persistent infection and impaired bone healing. Specific treatment requires initial antibacterial immune activation against infection, followed by resha...

2026-03-19 | MTBLS14091 | MetaboLights

Sigal2019 - Mathematical modelling of cancer stem cell-targeted immunotherapy

This is a mathematical model studies how specific immune system components, namely dendritic cells and cytotoxic T-cells, interact with different cancer cell types, specifically cancer stem cells (CSCs) and non-CSCs. The effects of two types of immunotherapy are modeled, namely dendritic cell vaccin...

2019-11-27 | MODEL1911270001 | BioModels

Immuno-oncology

PD-1-targeted immunotherapy in NASH-triggered liver cancer induces pro-tumorigenic environment through CD8+PD-1+ T-cells

Immunotherapy has opened hitherto unknown possibilities to treat cancer. Whereas some cancer types (e.g. melanoma) can be efficiently treated, others lack measurable positive effects (e.g. PDAC). Moreover, stratification of responders/non-responders is only possible in some cancer types (e.g. melano...

ORGANISM(S): Mus musculus (Mouse)

2021-03-03 | PXD017236 | Pride

Immunotherapy Cd8+pd1+ Nash

Evaluation of B7-H3 Targeted Immunotherapy in a 3D Organoid Model of Craniopharyngioma.

Not available

S-EPMC9775874 | biostudies-literature

Combination of Immunotherapy With Targeted Therapy: Theory and Practice in Metastatic Melanoma.

Not available

S-EPMC6513976 | biostudies-literature

Proteogenomic Discovery of Neoantigens Facilitates Personalized Multi-antigen Targeted T cell Immunotherapy for Brain Tumors

Neoantigen discovery in pediatric brain tumors is hampered by their low mutational burden and scant tissue availability. We developed a low-input proteogenomic approach combining tumor DNA/RNA sequencing and mass spectrometry proteomics to identify tumor-restricted (neoantigen) peptides arising from...

ORGANISM(S): Homo sapiens (Human)

2021-11-02 | PXD029082 | Pride

Lc-msms Medulloblastoma Pediatric brain tumors

Acquired resistance to targeted therapy confers cross-resistance to immunotherapy

PRJNA548090 | ENA

Multi-omics analysis reveals the sensitivity of immunotherapy for unresectable non-small cell lung cancer

Peripheral blood plasma was collected from unresectable stage III and IV non-small cell lung cancer patients who were negative for driver mutations before receiving immunotherapy. Then we classified samples according to the follow-up results after two courses of immunotherapy and non-targeted metabo...

ORGANISM(S): Homo Sapiens

2024-12-18 | PXD058967 |

Targeted Activation of JAML+ CD8+ T Cells Enhances Immunotherapy in Hepatocellular Carcinoma

PRJNA1170182 | ENA

Previous page
1 / 861
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 861
Next page

Sort by:

Relevance

Page size

8603 Results

Show results for

Organisms

Organisms

Repository

Tissue

Disease

Technology Type

Instrument Platform

Publication Date

CHEBI ID

Metabolite Name

First Public Date

Modelling Approach

Study status

Lab affiliation

Tags

Keyword

IsPrivate

Submitter Keywords

Classification

Study type

Release Date

Location

OmicsDI is part of the ELIXIR infrastructure

Tweets